AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL is a phase 3 interventional study registered as NCT07215585, led by AstraZeneca, and recruiting on the registry. Official title: A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 Followed by AZD0486 Versus R-mini-CHOP x6 in Elderly or Unfit Participants With Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2). Planned enrolment is 420 participants (estimated). The study started in 2025-11-11 and primary completion is expected in 2030-06-10. No results have been posted on ClinicalTrials.gov.